BALAXI23.09

BALAXI PHARMACEUTICALS LIMITED

· Unclassified
₹ CrorePeersPARSTEELCITYLATTEYSCROWNHECPROJECTHINDCONAIROLAMGROBTEAMcap ₹127 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)233.07172.88201.96201.96
Receivable Days (DSO)84.26138.23183.87183.87
Payable Days (DPO)82.3735.640.000.00
Cash Conversion Cycle (days)234.96275.47385.83385.83
Working Capital Turnover1.551.551.281.33
Asset Turnover0.930.940.800.80
Cash Conversion (CFO/Net Income)-2.04-1.40-3.18-3.18
CFO/EBITDA0.10-0.94-0.53-0.53
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.